{"id":"NCT01178294","sponsor":"Baxalta now part of Shire","briefTitle":"Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A","officialTitle":"Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-11-10","primaryCompletion":"2013-07-01","completion":"2013-10-09","firstPosted":"2010-08-10","resultsPosted":"2015-12-21","lastUpdate":"2021-05-13"},"enrollment":29,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"OBI-1","otherNames":[]}],"arms":[{"label":"OBI-1","type":"EXPERIMENTAL"}],"summary":"This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.","primaryOutcome":{"measure":"Percentage of Serious Bleeding Episodes Responsive to OBI-1","timeFrame":"24 hours after initiation of treatment","effectByArm":[{"arm":"OBI-1","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":12,"countries":["United States","Canada","India","United Kingdom"]},"refs":{"pmids":["25623166","39228858"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":29},"commonTop":["Constipation","Diarrhea","Hypokalemia","Anemia","Peripheral edema"]}}